Menu
Search
|

Menu

Close
X

Merrimack Pharmaceuticals Inc MACK.OQ (NASDAQ Stock Exchange Global Market)

10.95 USD
+0.05 (+0.46%)
As of 2:39 PM GMT
chart
Previous Close 10.90
Open 10.93
Volume 3,288
3m Avg Volume 51,377
Today’s High 10.95
Today’s Low 10.93
52 Week High 39.85
52 Week Low 9.69
Shares Outstanding (mil) 13.28
Market Capitalization (mil) 187.24
Forward P/E --
Dividend (Yield %) 10.55 ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
89
FY15
89
EPS (USD)
FY17
-4.384
FY16
-12.136
FY15
-13.240
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
2.10
5.77
Price to Book (MRQ)
vs sector
1.76
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
45.92
16.52
LT Debt to Equity (MRQ)
vs sector
45.92
12.22
Return on Investment (TTM)
vs sector
-113.12
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Gary Crocker
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Richard Peters
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Jean Franchi
Chief Financial Officer,Principal Financial Officer, Principal Accounting Officer, Treasurer, Since 2017
Salary: --
Bonus: --
John Green
Controller, Since 2017
Salary: --
Bonus: --
Ellen Forest
Head of Human Resources, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Kendall Sq Ste B7201
CAMBRIDGE   MA   02139-1670

Phone: +1617.4411000

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.

SPONSORED STORIES